Get the Stockscreener App
73.95
0.61%
0.4509
Henry Schein Inc stock is traded at $73.95, with a volume of 223.22K.
It is up +0.61% in the last 24 hours and down -5.33% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$73.50
Open:
$73.56
24h Volume:
223.22K
Relative Volume:
0.15
Market Cap:
$8.42B
Revenue:
$13.18B
Net Income/Loss:
$419.00M
P/E Ratio:
22.61
EPS:
3.2704
Net Cash Flow:
$521.00M
1W Performance:
+1.68%
1M Performance:
-5.33%
6M Performance:
+0.74%
1Y Performance:
+3.67%
1-Day Range:
$73.50
$74.81
1-Week Range:
$71.66
$74.81
52-Week Range:
$61.95
$89.29
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
73.95 | 8.37B | 13.18B | 419.00M | 521.00M | 3.2704 |
MCK
Mckesson Corp
|
764.58 | 92.14B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
275.31 | 51.64B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
201.13 | 46.98B | 250.74B | 1.55B | 4.39B | 6.5398 |
AHG
Akso Health Group Adr
|
1.50 | 1.29B | 14.85M | -136.07M | 7.25M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-26 | Initiated | BTIG Research | Neutral |
| Apr-15-26 | Initiated | Citigroup | Buy |
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein, Inc. (HSIC) Announces Key Decisions from 2026 Annu - GuruFocus
Henry Schein Names New Board Chairman - Dentistry Today
Henry Schein announces the election of William K. "Dan" Daniel as independent chairman of the board - marketscreener.com
Henry Schein appoints William Daniel as independent chairman - Investing.com
Dan Daniel becomes Henry Schein (HSIC) independent chair as Bergman retires - Stock Titan
Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board - Business Wire
Henry Schein (HSIC) director Stanley Bergman gifts 1,040 shares - Stock Titan
Henry Schein stock: Is Wall Street bullish or bearish? - MSN
Henry Schein stock (US42548G1040): Q1 2026 results and outlook update put margins in the spotlight - AD HOC NEWS
Assessing Henry Schein (HSIC) Valuation After Recent Uneven Share Price Performance - Yahoo Finance
Henry Schein Stock: Is Wall Street Bullish or Bearish? - Barchart.com
Henry Schein stock (US42548G1040): Q1 results and outlook update draw investor focus - AD HOC NEWS
Henry Schein, Inc. (HSIC) Stock Analysis: Exploring a 19.93% Potential Upside in Medical Distribution - DirectorsTalk Interviews
Henry Schein Highlights Dental Momentum, $125M Savings Goal Despite Medical Softness - MarketBeat
A Look At Henry Schein (HSIC) Valuation After Solid Q1 Update And Reaffirmed Guidance - Sahm
Why Henry Schein (HSIC) is a top value stock for the long term - MSN
Citigroup initiates coverage of Henry Schein (HSIC) with buy recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD) - The Globe and Mail
LONE PEAK VALUE FUND's Henry Schein Inc(HSIC) Holding History - GuruFocus
An Insider Of Henry Schein Picks Up 100% More Stock - simplywall.st
5 Must-Read Analyst Questions From Henry Schein’s Q1 Earnings Call - Yahoo Finance
Henry Schein Inc (HSIC) Stock Up 4.5% and Still Undervalued -- G - GuruFocus
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Henry Schein One Releases 2026 Catalyst Index - Dentistry Today
Henry Schein One Releases 2026 Catalyst Index, Revealing Clinical Performance as the Primary Driver of Growth - 01net
Henry Schein (HSIC) director boosts stake with 10,000-share open-market buy via trust - Stock Titan
Henry Schein beats Q1 earnings with $1.32 EPS, 6.3% revenue growth - eciks.org
Henry Schein : 2026 Proxy Supplement May 12, 2026 of 2025 - marketscreener.com
Right to Read, but Wrong to Write - Health API Guy
Henry Schein, Inc Receives Shareholder Proposal from John Chevedden - marketscreener.com
Henry Schein Inc. stock underperforms Monday when compared to competitors - MarketWatch
Henry Schein, Inc. $HSIC Holdings Increased by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Henry Schein stock (US42548G1040): Dental and medical distributor reports Q1 results and raises outl - AD HOC NEWS
Henry Schein stock (US42548G1040): Q1 2026 results and buyback drive sentiment - AD HOC NEWS
Barclays Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $86 - Moomoo
Henry Schein tops expectations, but shares dip slightly after results - MSN
Henry Schein Inc stock (US8064071025): Dental and medical distributor reports Q1 results and raises - AD HOC NEWS
Henry Schein, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - Moomoo
Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next - simplywall.st
Earnings Beat: Henry Schein, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Henry Schein Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analysts Are Bullish on Top Healthcare Stocks: Henry Schein (HSIC), Alphatec Holdings (ATEC) - The Globe and Mail
Number of shareholders of Henry Schein, Inc. – MIL:1HSIC - TradingView
Henry Schein Earnings Call Highlights Margin Momentum - The Globe and Mail
Henry Schein’s THRIVELIVE 2026 Delivers on Innovation, Education, and Inspiration - Dentistry Today
Henry Schein Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Research Alert: CFRA Maintains Hold Rating On Shares Of Henry Schein - Moomoo
Henry Schein Still Sees 2026 Adjusted Ebitda Up Mid-Single Digits >HSIC - Moomoo
Here's why Henry Schein (HSIC) is a strong value stock - MSN
Transcript: Henry Schein Q1 2026 Earnings Conference Call - Sahm
UBS Adjusts Price Target on Henry Schein to $85 From $87, Maintains Neutral Rating - marketscreener.com
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.00%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):